Results 121 to 130 of about 69,629 (300)

Convergence Deficits in Myoclonus‐Dystonia Point to Cerebellar Impairment

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Myoclonus‐dystonia (M‐D) is a monogenic movement disorder, with proposed cerebellar dysfunction. Vergence eye movement deficits, characteristics of degenerative cerebellar disease, have not been studied in M‐D. Cerebellar transcranial alternating current stimulation (tACS) is considered a potential therapeutic approach.
Skadi Gerkensmeier, Christina Bolte, Jan‐Ole Radecke, Feline Hamami, Andreas Sprenger, Christoph Helmchen, Robert Chen, Marcus Callister, Talyta Cortez Grippe, Christine Klein, Norbert Brüggemann, Tobias Bäumer, Alexander Münchau, Anne Weissbach   +13 more
wiley   +1 more source

The Value of Multidisciplinary Care in Parkinson\u27s Disease [PDF]

, 2003
Educational Objectives 1. To recognize the signs and symptoms of Parkinson\u27s disease (PD). 2. To identify key treatment and management strategies for PD. 3.
Baron, Mark, Hirsch, Miriam
core   +1 more source

Severity‐Based and Family‐Centered Approaches to Deep Brain Stimulation in GNAO1‐Related Disorders

Movement Disorders Clinical Practice, EarlyView.
Jana Domínguez‐Carral, Juan Darío Ortigoza‐Escobar   +1 more
wiley   +1 more source

Patient Selection in Deep Brain Stimulation: A Role for Transcranial Direct Current Stimulation to Enhance the Levodopa Challenge?

Annals of Clinical and Translational Neurology
Dopaminergic medication and deep brain stimulation (DBS) improve motor symptoms in Parkinson's disease (PD), but levodopa response alone may not predict DBS outcomes.
Lukas L. Goede, Patricia Zvarova, Bahne H. Bahners, Andreas Horn   +3 more
doaj   +1 more source

Highly efficient electrocatalytic oxidation of levodopa as a Parkinson therapeutic drug based on modified screen-printed electrode

Heliyon
The current study presents the creation of a straightforward and sensitive sensor based on ZnO/Co3O4 nanocomposite modified screen-printed electrode (ZnO/Co3O4NC/SPE) for levodopa determination. At ZnO/Co3O4NC/SPE, an oxidative peak for levodopa solution
Tan Wang, Nadhir N.A. Jafar, Afrah Majeed Ahmed Al-Rihaymee, Dheyaa Yahaia Alhameedi, Fadhil A. Rasen, Furqan S. Hashim, Talib Kh Hussein, Montather F. Ramadan, Kasim Kadhim Alasedi, Muath Suliman, Ahmed Hussien Alawadi   +10 more
doaj   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Impact of a Public Health Policy on Accessibility to Levodopa for People with Parkinson's Disease in Brazil

Movement Disorders Clinical Practice, EarlyView.
Juliana dos Santos Duarte, Laís Resque Russo Pedrosa, Rafael Sidônio Gibson Gomes, Bruno Lopes Santos‐Lobato   +3 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D., Barghshoon, Sami, Chen, Ching-Kang, Cheyette, Benjamin N. R., Ebert, Jana, Kovoor, Abraham, Lester, Henry A., Schwarz, Johannes, Schwarz, Sigrid, Seyffarth, Petra, Simon, Melvin I.   +10 more
core  

To Exercise at High Intensity Heart Rate or Not to Exercise at High Intensity Heart Rate?

Movement Disorders Clinical Practice, EarlyView.
Daniel M. Corcos, Guillaume Lamotte, Nijee S. Luthra, Kathleen E. McKee   +3 more
wiley   +1 more source